Rulo Radiofrequency Lesion Probe

K190256 · Epimed International, Inc. · GXI · Mar 8, 2019 · Neurology

Device Facts

• Record ID: K190256
• Device Name: Rulo Radiofrequency Lesion Probe
• Applicant: Epimed International, Inc.
• Product Code: GXI · Neurology
• Decision Date: Mar 8, 2019
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 882.4725
• Device Class: Class 2
• Attributes: Therapeutic, 3rd-Party Reviewed

Intended Use

The Rulo™ Radiofrequency Lesion Probe is an injection probe which may be used either for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning. A nerve is localized either by using electrostimulation through the needle or by injecting contrast medium through the needle and using radiography concomitantly. The nerve may then be blocked by injecting local anesthetic solution or a radiofrequency lesion may be made.

Device Story

Rulo Radiofrequency Lesion Probe is a single-use, surgically invasive device used by physicians in clinical settings to treat pain. It functions as an injection probe and RF electrode. The device is inserted into the spine using a flexible introducer accessory. Nerve localization is achieved via RF electrostimulation or contrast medium injection under radiography. Once localized, the device delivers RF energy to create a lesion on pain-conducting nerve tissue or delivers local anesthetic for nerve blocks. The probe features a directional active tip to focus energy and fluid delivery. The device connects to an external RF generator. By disrupting electrical signal conduction in targeted nerves, the device provides pain relief.

Clinical Evidence

Bench testing only. Performance testing included biocompatibility (ISO 10993-5, -10, -11), mechanical testing (ISO 594-1, ISO 594-2, ISO 7864), and safety/performance standards (ANSI/AAMI/EN 60601-1, BS 6196). No clinical data provided.

Technological Characteristics

Constructed of steel cannula with polymer insulation, hub, cable, connector, cap, and PVC fluid injection port. Features directional active tip for focused energy/fluid delivery. Connects to external RF generators. Dimensions: 16G and 18G models. Biocompatibility per ISO 10993. Standards: ISO 594-1/2 (Luer tapers), ISO 7864 (needles), ANSI/AAMI/EN 60601-1 (electrical safety), BS 6196 (epidural needles).

Indications for Use

Indicated for percutaneous nerve blocks with local anesthetic or radiofrequency lesioning to treat pain by disrupting nerve tissue conduction.

Regulatory Classification

Identification

A radiofrequency lesion probe is a device connected to a radiofrequency (RF) lesion generator to deliver the RF energy to the site within the nervous system where a lesion is desired.

Predicate Devices

• Diros OWL Sterile Single Use R.F. Insulated Cannulae Models 466 and DHC (K141586)

Reference Devices

• Flexible introducer accessory (K051860)
• Fluid injection port/extension set (K020926)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

March 8, 2019

Epimed International, Inc. % Mark Job Responsible Third Party Official Regulatory Technology Services, LLC 1394 25th Street, NW Buffalo, Minnesota 55313

Re: K190256

Trade/Device Name: Rulo Radiofrequency Lesion Probe Regulation Number: 21 CFR 882.4725 Regulation Name: Radiofrequency lesion probe Regulatory Class: Class II Product Code: GXI Dated: February 5, 2019 Received: February 7, 2019

Dear Mark Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Matthew C. Krueger -S

for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K190256

Device Name RuloTM Radiofrequency Lesion Probe

#### Indications for Use (Describe)

The RuloTM Radiofrequency Lesion Probe is an injection probe which may be used either for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning. A nerve is localized either by electrostimulation through the needle or by injecting contrast medium through the needle and using radiography concomitantly. The nerve may then be blocked by injecting local anesthetic solution or a radiofrequency lesion may be made.

| Type of Use (Select one or both, as applicable) | |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <span> <span></span>Prescription Use (Part 21 CFR 801 Subpart D) </span> | <span> <span></span>Over-The-Counter Use (21 CFR 801 Subpart C) </span> |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for "Epimed", a company that designs products for experts. The logo features a red triangle on the left side, followed by the company name in bold, black letters. Below the company name, there is a tagline that reads "Designed by Experts for Experts" in a smaller font.

# 510(k) Summary: K190256

#### Submitter Information:

| Name:<br>Address: | Epimed International, Inc.<br>13958 Diplomat Drive<br>Farmers Branch, Texas 75234 |
|--------------------------------------|-----------------------------------------------------------------------------------|
| Telephone Number: | [phone] |
| Fax Number: | [phone] |
| Contact Person:<br>Telephone Number: | Preston H. Frasier<br>Manager – QA/RA<br>[phone] Ext. 1300 |
| Email Address: | [e-mail] |
| Date Prepared: | January 23, 2019 |

# Device Name & Classification:

| Device Trade Name: | Rulo™ Radiofrequency Lesion Probe |
|-----------------------|----------------------------------------------------|
| Common Name: | Radiofrequency Lesion Probe |
| Classification Names: | Radiofrequency Lesion Probe, GXI (21 CFR 882.4725) |
| Models/Sizes: | 300-1615 (16 gauge); 300-1815 (18 gauge) |

## Predicate Device(s) Information:

Predicate Device: Diros OWL Sterile Single Use R.F. Insulated Cannulae Models 466 and DHC (K141586)

# Device Description:

The Rulo™ Radiofrequency Lesion Probe (Rulo Probe) creates radiofrequency

(RF) lesions on nerves and can also create percutaneous nerve blocks by

delivering anesthetic to the site. It is a single-use, surgically invasive device. It is

Page 1

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image is a logo for a company called "Epimed". The logo consists of a red triangle on the left side and the company name in black letters on the right side. Below the company name is the text "Designed by Experts for Experts" in a smaller font.

inserted with the use of a flexible introducer accessory to contact a nerve in an area of the spine for less than 15 minutes to treat pain. The RF energy creates a lesion on nerve tissue that conducts pain signals. The tissue's ability to conduct electrical signals is disrupted by the lesion. The targeted nerve can be localized either by using RF electrostimulation through the cannula or by injecting contrast medium through the cannula with the use of the fluid injection port and using radiography concomitantly. The nerve may be blocked by injecting local anesthetic solution or making an RF lesion. The device is used by a trained physician in a clinical setting.

The device is constructed with a steel cannula and uses a variety of polymers for the insulation, hub, cable, connector, cap and fluid injection port

The flexible introducer accessory was cleared in K051860. The fluid injection port was cleared as an extension set in K020926.

## Statement of Intended Use:

The Rulo™ Radiofrequency Lesion Probe is an injection probe which may be used either for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning. A nerve is localized either by using electrostimulation through the needle or by injecting contrast medium through the needle and using radiography concomitantly. The nerve may then be blocked by injecting local anesthetic solution or a radiofrequency lesion may be made.

The Rulo Radiofrequency Lesion Probe Intended Use/Indications for Use statement is essentially identical to that of the predicate device, Diros OWL Sterile Single Use R.F. Insulated Cannulae Models 466 and DHC (K141586).

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for "Epimed". The logo consists of a red triangle on the left, followed by the word "Epimed" in bold, black letters. Below the word "Epimed" is the tagline "Designed by Experts for Experts" in a smaller, lighter font. The logo appears to be for a company or organization that specializes in expert-designed products or services.

# Technological Characteristics and Substantial Equivalence:

The Rulo Probe is similar in design and material composition to the predicate device, Diros OWL Sterile Single Use R.F. Insulated Cannulae Models 466 and DHC (K141586). Both have an insulated steel needle (cannula) where the opening in the insulation at the tip of the device delivers radiofrequency energy and fluid to the tissue it contacts. Both devices connect to radiofrequency generators and have a fluid port. The uninsulated delivery site on the cannula of the Rulo Probe is directional and can focus the energy and fluid to the desired tissue target while the Diros predicate device does not have the directional feature. The Diros device has a sharp tip for direct insertion into the tissue while the Rulo Probe is inserted with a flexible introducer accessory.

### Nonclinical Testing:

The results of the performance testing, demonstrate that the Epimed Rulo™ Radiofrequency Lesion Probe performs comparably to and is substantially equivalent to the predicate device (K141586).

There is not a harmonized standard or quidance document that directly applies to radiofrequency lesion devices. Applicable tests and requirements have been adopted from the following standards to compile the suite of performance testing:

ISO 594-1 Conical fittings with a 6% (Luer) taper for syringes, needles and certain other medical equipment - Part 1: General requirements

ISO 594-2 Conical fittings with a 6% (Luer) taper for syringes, needles and certain other medical equipment - Part 1: Lock Fittings

BS 6196 British Standard Specification for Sterile Epidural Catheters and Introducer Needles for Single Use

ANSI/AAMI/ EN 60601-1 Medical Electrical Equipment – Part 1: General Requirements for Basic Safety and Essential Performance

ISO 7864 Sterile Hypodermic Needles for Single Use

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for "Epimed", which is written in bold, black font. To the left of the word is a red triangle. Below the word "Epimed" is the phrase "Designed by Experts for Experts" in a smaller, lighter font.

In accordance with the applicable sections recommended per ISO 10993-1, the relevant patient contacting components have been shown to meet the necessary biocompatibility requirements. The biocompatibility of the materials used to manufacture the Rulo Probe have been tested and analyzed with discussion in the Biocompatibility Assessment. The biocompatibility testing which has been performed includes the following:

- . Cytotoxicity (per ISO 10993-5)
- Sensitization (per ISO 10993-10) .
- . Irritation or Intracutaneous Reactivity (per ISO 10993-10)
- Systemic Toxicity (per ISO 10993-11) .

The flexible introducer accessory is made of stainless steel and was cleared in K051860. The fluid port is made of PVC and was cleared as an extension set in K020926.

# Conclusions:

Epimed's Rulo Radiofrequency Lesion Probe and the predicate device, Diros OWL Sterile Single Use R.F. Insulated Cannulae Models 466 and DHC (K141586), have the same intended use/indications for use and the probes are very similar in technological characteristics, including the overall design, dimensions, delivery of RF energy and fluids, and choice of materials.

There are some minor differences in technological characteristics that do not raise new questions of safety or efficacy. The predicate device has an active tip that does not direct the energy or fluids in a specific direction. The Rulo Probe has a focused active tip for directionality in delivery of RF energy, and this direction is indicated by the handle. The predicate device has a sharper tip and can be inserted directly into the tissues, the while Rulo Probe has a blunt tip, and is inserted into the tissue with the use of a flexible introducer accessory. This accessory has been cleared in in the marketplace for several years, and does not present any new questions of safety or efficacy.

Page 4

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for "Epimed". The logo consists of a red triangle on the left, followed by the word "Epimed" in bold, black letters. Below the word "Epimed" is the phrase "Designed by Experts for Experts" in a smaller font.

In additional to the same intended use, the technological characteristics are the same or similar, and where there are minor differences, there are not new or different questions of safety or efficacy, as demonstrated by bench and laboratory testing. Epimed's Rulo Radiofrequency Lesion Probe is substantially equivalent to the predicate device.